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Abstract
Introduction: Puberty is a period of increased susceptibility to factors that cause increased breast cancer risk in
adulthood. Mammary end buds (EBs) that develop during puberty are believed to be the targets of breast cancer
initiation. Whereas the role of estrogen (E) has been extensively studied in pubertal mammary gland development,
the role of progesterone (P) during puberty is less defined.
Methods: Pubertal and prepubertal ovariectomized mice were treated with vehicle control (C), E, P, or E+P.
Mammary glands from these mice were analyzed for changes in morphology, proliferation, and expression of the
downstream targets amphiregulin (AREG) and receptor activator of NF-B ligand (RANKL).
Results: P, acting specifically through the progesterone receptor, induced increases in mammary gland
proliferation and EB formation that were associated with increased AREG expression in ducts and EBs. E, acting
specifically through the estrogen receptor, produced similar responses also mediated by AREG. Blocking AREG
action by treatment with an EGFR inhibitor completely abrogated the effect of P on EB formation and proliferation
and significantly reduced proliferation within ducts. P also increased expression of RANKL, primarily in ducts.
Treatment with RANK-Fc, an inhibitor of RANKL, reduced P-dependent proliferation in ducts and to a lesser extent
in EB, but did not cause EB regression.
Conclusions: These results demonstrate a novel P-specific effect through AREG to cause EB formation and
proliferation in the developing mammary gland both before and during puberty. Thus, hormones and/or factors in
addition to E that upregulate AREG can promote mammary gland development and have the potential to affect
breast cancer risk associated with pubertal mammary gland development.
Introduction
The mouse mammary gland is used as a model for
development of the human breast. Before puberty, both
the mouse and human mammary glands grow and
develop at an isometric rate, at the same rate as the
body. At puberty, rapid changes in the hormonal milieu
drive increased proliferation and expanded ductal devel-
opment to fill the fat pad (reviewed in [1]). During this
time, highly proliferative structures called end buds
(EBs) are present at the leading growth front of ducts in
the gland (reviewed in [2]). EBs progress into the mam-
mary fat pad, and the ductal network is formed by bifur-
cation of the EBs and branching of ducts until the fat
pad is filled with an extensive, branched ductal system.
As the mammary gland reaches the limits of the fat pad,
these EB structures regress and disappear.
There is increasing interest in factors influencing pub-
ertal mammary gland development and breast cancer risk
later in life [3]. EB structures are sensitive to chemical
carcinogens [4,5], and compounds that influence EB for-
mation could alter the sensitivity of the mammary gland
to chemical carcinogen action. In mouse and rat models
of mammary carcinogenesis, the peripubertal period
shows increased sensitivity to carcinogen exposure and
mammary cancer development [6-8]. During adoles-
cence, maturation of the hypothalamic-pituitary-ovarian
axis, the regulator of ovarian hormone production,
occurs along with the majority of breast development. Of
particular interest are factors, such as endocrine disrup-
tors, that may influence ovarian hormone production or
hormone action in the developing mammary gland. To
understand factors that influence hormone action, it is
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important to first have an understanding of the mechan-
isms of normal hormone responses in the mammary
gland.
The ovarian hormone estrogen (E) is the primary hor-
mone required for ductal development during puberty
[9], whereas the role of progesterone (P) during puberty
is less defined. P acting through the progesterone recep-
tor (PR) is not essential for pubertal mouse mammary
gland growth, as the PR knockout (PRKO) mouse com-
pletes ductal development successfully [10]. Despite this,
a role for P and PR during puberty is indicated by a
delay in ductal development in mice treated with the
PR-antagonist RU486 and in the PR-knockout (PRKO)
mouse [11]. In addition, treatment of IGF-I-/- mice with
IGF-I plus P is capable of stimulating mammary gland
development in the absence of E, suggesting that P has
E-independent effects in the pubertal mammary gland
[12]. A role for P in increasing ductal branching during
puberty has also been demonstrated [13-15]. Consistent
with pubertal P being important for both normal devel-
opment and breast cancer development, supplementa-
tion of carcinogen-treated pubertal rats with E + P
results in higher tumor incidence than does treatment
with E alone [16]. Thus, P and PR can play an impor-
tant role in pubertal mammary gland development, and
may also be involved in increased cancer susceptibility
during puberty. However, no mechanism for P action in
the pubertal mammary gland has been described.
In this study, we sought to elucidate further the role of
P in pubertal ductal development. We found that P act-
ing through PR caused pubertal EB formation, which was
dependent on an increase in amphiregulin (AREG)
expression. P-induced AREG was associated with prolif-
eration in both the EBs and ducts. P also increased
expression of receptor activator of NF-B ligand
(RANKL), a known paracrine mediator of P, which pri-
marily affected proliferation in ducts. Further showing
the importance of AREG downstream of P, we found that
the prepubertal mammary gland was highly sensitive to
low doses of P that also increased AREG expression and
led to EB formation. These studies further emphasize the
importance of AREG for EB formation in the pubertal
gland and demonstrate that hormones and/or factors, in




BALB/c and C57BL/6 mice were purchased from Harlan
(Indianapolis, IN, USA) and Jackson Laboratory (Bar
Harbor, ME, USA), respectively. Two time frames of
mammary gland development were examined. In the
first case, pubertal 4-week-old BALB/c and C57BL/6
mice that initiated estrus cycling and exhibited EBs were
ovariectomized (OVX). Three weeks post-OVX recovery
was allowed for complete EB regression before hormone
treatments [17]. OVX mice were injected daily for 5 days
with saline control (C), 17-b-estradiol (E2) (1 μg/inj),
progesterone (P) (1 mg/inj), or E2+P (1 μg + 1 mg/inj,
respectively). These concentrations of E2 and P have
been used in previous studies to examine the effects of
E2 and P in the adult mammary gland and were used to
compare pubertal versus adult sensitivity and responses
to the hormones [18]. To block PR-mediated effects,
anti-progestin RU486 (1.3 mg/inj) (mifepristone; Sigma,
St. Louis, MO, USA) was co-injected with P. To block
estrogen receptor (ER)-mediated effects, anti-estrogen
ICI 182,780 (ICI) (1.1 μg/inj) (Tocris Bioscience, Ellisville,
MO, USA) was co-injected with E2. To block epidermal
growth factor receptor (EGFR)-mediated effects, E2- and
P-treated mice were given gefitinib (Iressa; ChemieTek,
Indianapolis, IN, USA) (300 mg/kg dissolved in corn oil)
daily for 5 days by oral gavage. To block RANKL-
mediated effects, P-treated mice were co-injected with
RANK-Fc (20 mg/kg dissolved in saline) (R&D Systems,
Minneapolis, MN, USA) every other day for 5 days.
In the second case, prepubertal 3-week-old BALB/c
mice that had not started estrus cycles or EB formation
were OVX. Two weeks post-OVX mice received a single
injection with saline control (C), or low-dose E2 (0.1 μg),
P (0.1 mg), or E2+P (0.1 μg E + 0.1 mg P) with or without
5 mg ICI 182,780 (ICI) (Tocris Bioscience), and then
killed 48 hours later. Hormone dosages were based on
the minimal concentrations of E2 capable of EB forma-
tion in the pubertal gland [19]. To block local PR-
mediated effects in the mammary gland, elvax pellets
containing the anti-progestin RU486 (1 μg mifepristone;
Sigma) were implanted into the right number 4 mam-
mary gland of prepubertal OVX mice 2 weeks after OVX.
Control pellets were implanted into the left number 4
mammary gland. The following day, mice were given a
single injection of P (0.1 mg).
All mice were injected with 5-bromo-2’-deoxyuridine
(BrdU) (70 μg/g body weight) 2 hours before being
killed. Mammary glands were fixed and processed as
whole mounts [20], or paraffin-embedded for immuno-
histochemistry [21]. All animal experimentation was
conducted in accord with accepted standards of humane
animal care and approved by the All University Com-
mittee on Animal Use and Care at Michigan State
University.
Immunofluorescence
PR was detected by using mouse monoclonal anti-PR
(1:50; hPRa7; Neomarkers, Fremont, CA, USA). Estrogen
receptor a (ERa), AREG, RANKL, and BrdU were
detected by using mouse monoclonal anti-ERa (1:10;
Novocastra; Leica Microsystems Inc., Buffalo Grove, IL,
Aupperlee et al. Breast Cancer Research 2013, 15:R44
http://breast-cancer-research.com/content/15/3/R44
Page 2 of 15
USA), goat polyclonal anti-amphiregulin (1:100; R&D
Systems, Minneapolis, MN, USA), goat polyclonal anti-
RANKL (1:500; R&D Systems), or mouse monoclonal
anti-BrdU (undiluted; kit from Amersham Biosciences,
Piscataway, NJ, USA) primary antibodies followed by
appropriate secondary antibodies conjugated to Alexa
488 (Molecular Probes, Eugene, OR, USA) [21]. Double
labeling of PR or ERa with anti-BrdU antibody was as
described previously [21], by using appropriate secondary
antibodies conjugated to Alexa 488 or Alexa 546. Nuclei
were counterstained with 4’,6-diamidino-2-phenylindole,
dilactate (DAPI) (Molecular Probes). Sections were visua-
lized and images captured by using a Nikon inverted epi-
fluorescence microscope (Mager Scientific, Dexter, MI,
USA) with MetaMorph software (Molecular Devices Cor-
poration, Downington, PA, USA).
Quantitative RT-PCR
Whole mammary gland total RNA was extracted by
using TRIzol (Invitrogen, Carlsbad, CA, USA) following
the manufacturer’s suggested protocol. cDNA was pro-
duced by reverse transcription with random hexamer
primers and reverse transcriptase-polymerase chain
reaction (RT-PCR), and quantitation of murine amphire-
gulin (Mm00437583_m1) (Applied Biosciences, Carls-
bad, CA, USA) and 18S RNAs (Hs99999901_s1) was
performed, as previously described [22].
Quantitation and statistical analyses
BrdU and PR were quantitated for the number of positive
luminal epithelial cell nuclei from captured images by
using MetaMorph software, as previously described [18].
A minimum of three mice per treatment group and a
minimum of 500 cells in three independent sections per
mouse were analyzed for all experiments. Whole-mount
preparations of mammary gland number 4 or numbers
2/3 were scored for numbers of EBs. EBs were defined as
enlarged (>100 μm in diameter), multilayered ductal tips
surrounded by adipocytes and located at the periphery of
the gland. Results are expressed as mean ± SEM, and dif-
ferences are considered significant at P < 0.05 with the
Student t test or ANOVA, as appropriate.
Results
Morphologic and proliferative responses to hormones
during puberty
Before puberty and the onset of estrus cycles, mammary
ductal outgrowth is limited and hormone independent.
Increasing hormone levels during puberty produce loca-
lized mammary ductal proliferation at sites called end
buds (EBs) that drive ductal elongation (reviewed in
[23]). To examine the role of progesterone (P) during
puberty, 4-week-old mice were OVX to remove endogen-
ous hormone production and allow EB regression, and
then hormone-treated for 5 days. Two mouse strains
(BALB/c, C57BL/6) were used in these studies because
they showed differential sensitivity of the adult gland to P
[24]. Thus, it was of interest to determine whether the
differential P sensitivity also occurred in the pubertal
gland. Treatment of BALB/c mice for 5 days with P alone
stimulated EB formation (Figure 1A). The degree of sti-
mulation (EB formation) obtained with P alone was simi-
lar to that obtained with 17-b-estradiol (E2) alone, or
with E2 + P (Figure 1B). EBs were completely regressed
and absent in vehicle-treated controls. Limited side-
branching was observed in response to P or E2+P in the
pubertal mammary gland in contrast to the extensive
sidebranching normally seen in the adult BALB/c mam-
mary gland at the same hormone doses [24] (Figure 1C).
EB formation with P treatment was also obtained in
C57BL/6 pubertal mice (see Additional File 1, Figure
S1A). The similarity of the pubertal hormone responses,
particularly for P, between the BALB/c and C57BL/6
mice was in contrast to the significant differences in
mammary gland responses previously reported for P
treatment of adult mice [24].
Because P exerts its effects in the mammary gland
through the PR, PR protein expression and regulation
by hormone treatment in pubertal BALB/c mice was
examined with immunofluorescence (Figure 1D). P
treatment significantly decreased the percentage of PR
positive (PR+) luminal epithelial cells compared with
vehicle controls, whereas treatment with E2 or E2+P did
not significantly change the percentage of PR+ cells.
Hormonal regulation of PR expression was similar in
both BALB/c and C57BL/6 mice (see Additional File 1,
Figure S1B).
To distinguish between the mechanisms of P and E
action in pubertal EB formation, anti-estrogen and anti-
progestin were used to block E2 and P action through
their cognate receptors, ERa and PR. Anti-progestin
RU486 treatment inhibited P-induced EB formation and
treatment with the anti-estrogen ICI 182,780 inhibited
E2-induced EB formation (Figure 1E). Thus, the
observed effects of P on EB formation in the pubertal
mouse mammary gland were P-specific and mediated
through PR.
Proliferative response to hormones during puberty
The majority of proliferating cells in the adult mammary
gland are ER/PR negative [18,25], suggesting a paracrine
mechanism for hormone-induced proliferation. To
determine whether a similar paracrine mechanism for P-
induced proliferation occurred in the pubertal mammary
glands, DNA synthesis, as measured by BrdU uptake
into hormone-receptor positive versus negative cells,
was analyzed by examining co-localization of BrdU with
PR expression (Figure 1F).
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The percentage of BrdU-positive (BrdU+) cells was sig-
nificantly increased throughout the mammary gland in
both ducts and EBs by E2, P, and E2+P treatment (Figure
1F). A significant percentage of PR-positive (PR+) cells
incorporated BrdU in the pubertal mammary gland after
hormone treatment. Treatment with E2, P, or E2+P pro-
duced similar BrdU uptake in PR+ cells and represented
about one third of the total BrdU+ cells in EBs (Figure
1F). The overall percentages of BrdU+ cells and BrdU
uptake in PR+ cells were significantly higher in EBs than
Figure 1 Both 17-b-estradiol and progesterone induce similar morphologic and proliferative responses in the pubertal mammary
gland. Pubertal 4-week-old BALB/c mice were OVX, allowed to recover for 3 weeks, and then treated for 5 days with vehicle control (C), E2, P,
or E2+P, as described in the Materials and Methods section. (A) Morphologic response to 5d C, E2, P, or E2+P. Note lack of EBs in controls and
similar presence of EBs in E2-, P-, and E2+P-treated glands. Scale bar, 1 mm. (B) End bud (EB) quantitation. Values represent the mean ± SEM
number of EBs in a number 4 mammary gland (n = 3 mice). (C) Morphologic response to 5d P in the adult 17-week-old BALB/c OVX mammary
gland; note presence of extensive side branching. Scale bar, 1 mm. (D) Immunofluorescent detection of PR expression in luminal cells. The
values represent the mean ± SEM percentage PR-positive cells (n = 3 animals per treatment). The percentage PR-positive cells in 5-day P-treated
BALB/c mice was less than control (*P < 0.05). (E) Inhibition of EB formation by E2+ ICI 182,780 and P+RU486. Scale bar, 1 mm. (F) Proliferation
analysis by dual immunofluorescent detection of BrdU and PR. The total percentages BrdU-positive cells and BrdU-positive cells co-expressing PR
in ducts and EBs are presented. The values represent the mean ± SEM (n = 3 animals per treatment). The percentage of BrdU-positive luminal
epithelial cells in ducts after E2, P, or E2+P treatment was greater than control (*P < 0.05). The percentage of BrdU-positive cells was greater in
EBs than in ducts after E2, P, or E2+P treatment (#P < 0.05).
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in ducts. Similar results for the overall percentages of
BrdU+ cells and BrdU uptake in PR+ cells were obtained
in the C57BL/6 mammary gland (see Additional File 1,
Figure S2). These BrdU-uptake results demonstrate an
increased proliferative response of PR+ cells to hormones
in the pubertal mammary gland compared with the adult
gland [18], and show a similar pattern of proliferative
response in the two mouse strains.
Amphiregulin mediates P- and E2-induced proliferation
The similarities between E2- and P-induced EB forma-
tion and proliferative responses and the lack of addi-
tional increases in proliferation with combined E2 + P,
suggested a common mechanism of action for both hor-
mones. Ciarloni et al. [19] previously established that E-
induced amphiregulin (AREG) in mammary epithelial
cells is a paracrine mediator of EB formation. AREG is
the most highly expressed epidermal growth factor
receptor (EGFR) ligand in ducts and end buds during
puberty, and AREG is required for normal ductal mor-
phogenesis [26]. P has also been shown to increase
AREG expression in the adult mouse mammary gland
[27] and mouse uterus [28]. Given the functional signifi-
cance of AREG in E-induced EB formation, its high
expression in the pubertal mammary gland compared
with other EGFR ligands, and reported regulation of
AREG by P, we hypothesized that P-induced EB forma-
tion was also mediated by AREG.
Analysis of Areg expression with RT-PCR in the 5-day
hormone-treated pubertal mammary gland showed that
Areg mRNA expression was significantly increased by 5-
day treatment with P (30.8 fold), E2 (24.0 fold), and E2+P
(39.6 fold) compared with vehicle controls (Figure 2A).
AREG protein expression also increased in the pubertal
mammary gland in response to 5-day treatment with E2,
P, or E2+P (Figure 2B). Similar increases in AREG pro-
tein expression were also observed after hormone treat-
ment in the C57BL/6 strain of mice (Additional File 1,
Figure S3A). The E2-induced increase in AREG expres-
sion was blocked by the ERa antagonist ICI 182,780, and
P-induced AREG expression was blocked by the PR
antagonist RU486 (Figure 2B). Pubertal AREG expression
in response to P was localized throughout the mammary
gland in both ducts and EBs (Figure 2C).
To examine further the role of AREG in pubertal P-
induced EB formation, the EGFR-inhibitor Iressa was used
to block AREG action through the EGFR. Inhibition of
EGFR by Iressa completely inhibited both E2- and P-
induced pubertal EB formation (Figure 3A, B) and EB pro-
liferation in the mammary gland (Figure 3C); no EBs were
present in mammary gland sections from Iressa-treated
mice (Figure 3A, B). The percentage of cells incorporating
BrdU within ducts in response to E2 was reduced by 98%
by Iressa (P < 0.01 versus E2), whereas the percentage of
BrdU+ cells in ducts in response to P was reduced 66% by
Iressa (P < 0.05 versus P).
RANKL in P-mediated proliferation
Receptor activator of NF-B ligand (RANKL) is another
downstream effector of P in the mammary gland [24,29].
Five-day P or E2+P treatment in the pubertal mammary
gland increased RANKL expression, whereas treatment
with E2 alone did not increase RANKL expression (Figure
4A). P-induced RANKL expression colocalized with PR
expression (Figure 4B) and was primarily localized to
ducts, and, to a lesser extent, in EBs. In contrast to BALB/c
mice, 5-day P treatment of C57BL/6 mice failed to increase
RANKL expression (Additional File 1, Figure S3B). How-
ever, both the pubertal BALB/c and C57BL/6 mammary
glands showed expression of RANKL in response to E2+P
treatment. These results indicate that P-induced RANKL is
not required for EB formation and proliferation in C57BL/
6 mice.
The potential role of RANKL downstream of P in EB
formation and proliferation in BALB/c mice was examined
by using the RANKL inhibitor RANK-Fc; RANK-Fc binds
RANKL and inhibits binding to its natural receptor, recep-
tor activator of NF-B (RANK). Treatment with RANK-Fc
had a small effect to reduce P-induced EB formation that
did not achieve statistical significance (P = 0.2) (Figure 4C,
D). In contrast, RANK-Fc significantly decreased prolifera-
tion by 58% in ducts (P < 0.05 versus P) and by 46% in
EBs (P < 0.05 versus P) (Figure 4E).
P-induced EB formation in prepubertal mice
To examine the sensitivity and response of the mammary
gland to P before the onset of puberty, 3-week-old BALB/
c mice were OVX and treated with a low dose of E2 or P
[19]. Notably, the single low-dose P treatment produced
EB formation similar to that observed with E2 (Figure 5A)
and similar to the results with 5-day P treatment during
puberty (Figure 1A). Control-treated mice had only rudi-
mentary mammary glands with no EBs present (Figure
5A). PR expression after low-dose hormone treatment was
detected at similar levels across all treatments (Figure 5B).
The anti-estrogen ICI 182,780 inhibited E2-induced EB
formation (Figure 6A), but not P-induced EB formation.
Treatment with the anti-progestin RU486 inhibited
P-induced EB formation (Figure 6B).
Similar to the 5-day treatment during puberty, BrdU
uptake in epithelial cells (PR+ and PR negative (PR-))
within EBs was significantly higher than in ducts after the
single low-dose treatment and was similar among E2, P,
and E2+P treatments (Figure 6C). Additionally, a sub-
stantial percentage of PR+ cells in both EBs and ducts
exhibited BrdU uptake (Figure 6C).
Analysis of Areg-encoding mRNA in the prepubertal
mammary gland by quantitative RT-PCR showed that
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Figure 2 Both 17-b-estradiol and progesterone regulate amphiregulin through their cognate receptors in the pubertal mammary
gland. Pubertal 4-week-old BALB/c mice were OVX, allowed to recover for 3 weeks, and then treated for 5 days with vehicle control (C), E2, P,
or E2+P, as described in the Materials and Methods section. (A) RT-PCR analysis of amphiregulin (AREG) in response to hormone treatments.
Fold change is relative to control treatment. (B) Immunofluorescent detection of AREG (green) in ducts after E2, E2+ICI, P, P+RU486, and after
P treatment in both ducts and end buds. Nuclei were counterstained with DAPI (blue). Scale bar, 25 μm.
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Areg expression was increased by single low-dose treat-
ment with P (5.66 fold) or E2 (22.95 fold) compared with
vehicle controls (Figure 7A). AREG protein expression, as
measured with immunofluorescence, also increased in the
prepubertal mammary gland in response to single low-
dose of either E2 or P treatment in ERa/PR-expressing
cells (Figure 7B, C) and was higher after low-dose E2 treat-
ment than after P treatment (Figure 7B). Within the mam-
mary epithelium, AREG was most strongly induced by P
in EBs (Figure 7C, EBs) and in ducts near EBs (Figure 5C,
duct near EBs). In ducts farthest from the EBs, AREG was
not detected (Figure 7C, duct near nipple). This gradient
Figure 3 Iressa inhibits both 17-b-estradiol and progesterone-induced proliferation and EB formation. Pubertal 4-week-old BALB/c mice
were OVX, allowed to recover for 3 weeks, and then treated for 5 days with vehicle control (C), E2 +/- Iressa (300 mg/kg), or P +/- Iressa, as
described in the Materials and Methods section. (A) EB formation after 5 days E2, E2+Iressa, P, or P+Iressa. Note the absence of EBs in Iressa-
treated mammary glands. Scale bar, 2 mm. (B) End bud quantitation. Values represent the mean ± SEM number of end buds in a number 4
mammary gland (n = 5 mice). (C) The percentage of proliferating cells in ducts and EBs was determined by immunofluorescence detection of
BrdU incorporation. P+Iressa treatment reduced proliferation in ducts relative to P treatment (*P < 0.05).
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Figure 4 Progesterone-induced RANKL expression contributes to the proliferative response in the pubertal mammary gland. Pubertal
4-week-old BALB/c mice were OVX, allowed to recover for 3 weeks, and then treated for 5 days with vehicle control (C), E2, P, or E2+P, as described in
the Materials and Methods section. (A) Immunofluorescent detection of RANKL (green) in P and E2+P-treated mammary glands. (B) Dual
immunofluorescent detection of RANKL (green) and PR (red) expression in representative images of an E2+P-treated duct and end bud. RANKL was
most strongly expressed in ducts. Nuclei (A, B) were counterstained with DAPI (blue). Scale bars, 25 μm. (C) Effect of 5d P versus 5-day P+RANK-Fc on
EB formation; note lack of significant EB regression with RANK-Fc treatment. Scale bar, 1 mm. (D) End-bud quantitation. Values represent the mean ±
SEM number of end buds in the thoracic mammary gland (n = 3 mice). (E) The percentage of proliferating cells in ducts and EBs was determined by
immunofluorescent detection of BrdU incorporation after C, P, and P+RANK-Fc treatment. P+RANK-Fc treatment had fewer proliferating cells in ducts
than in P treatment (*P < 0.05). P+RANK-Fc treatment had fewer proliferating cells in EB than in P treatment (#P < 0.05).
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Figure 5 Both 17-b-estradiol and progesterone induce morphologic responses in the prepubertal mammary gland. Prepubertal 3-week-
old BALB/c mice were OVX, allowed to recover for 2 weeks, and then treated once with vehicle control (C), E2, P, or E2+P, as described in the
Materials and Methods section. (A) End bud (EB) formation in response to C, E2, and P. Inset shows higher magnification of EB. Note similar EB
formation after E2 or P treatments. Scale bar, 1 mm. (B) PR expression. Immunofluorescent detection of PR-positive luminal cells. The values
represent the mean ± SEM percentage of PR-positive cells (n = 3 animals per treatment).
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Figure 6 Both 17-b-estradiol and progesterone-induced responses in the prepubertal mammary gland occur through their cognate
receptors. (A) Representative whole mounts from prepubertal 3-week-old BALB/c mice that were OVX, allowed to recover for 2 weeks, and then
treated once with vehicle control (C) + ICI 182,780 (ICI), E2 + ICI, or P + ICI, as described in the Materials and Methods section. Scale bar, 1 mm.
Inset shows higher magnification of end buds (EBs), which were present in only the P + ICI treatment group. Scale bar, 1 mm. (B) Effect of RU486
implant on P-induced EB formation. RU486 pellet implanted in the right mammary gland number 4, and control pellet implanted in the
contralateral number 4 mammary gland. Implants are outlined with dashed lines and noted with an asterisk. Note stimulated EB in control L4 gland
and nonstimulated duct ends (arrows). Scale bar, 2 mm. (C) Proliferation analysis by dual immunofluorescence detection of BrdU and PR. Total
percentage BrdU-positive cells and percentage BrdU-positive cells coexpressing PR in ducts and end buds after C, E2, P, or E2+P treatment are
presented. The percentage of BrdU-positive cells in ducts increased in response to E2, P, or E2+P treatment compared with control (*P < 0.05). The
percentage of BrdU-positive cells increased in end buds compared with ducts in E2, P, or E2+P (#P < 0.05).
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Figure 7 17-b-Estradiol regulates amphiregulin, and progesterone regulates both amphiregulin and RANKL in the prepubertal
mammary gland. Prepubertal 3-week-old BALB/c mice were OVX, allowed to recover for 2 weeks, and treated once with vehicle control (C), E2,
or P, as described in the Materials and Methods section. (A) Expression analysis of amphiregulin (AREG) by RT-PCR. Fold change is relative to
control treatment. (B) Dual immunofluorescence detection of AREG (green) and either ERa (red, on left) or PR (red, on right). AREG expression
increased in response to E2 or P in ERa-expressing cells and was most strongly expressed in end buds in response to P treatment. Nuclei were
counterstained with DAPI (blue). Scale bar, 25 μm.
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of AREG expression was observed for all three hormone
treatments, consistent with a preferential localization of
AREG in EBs and a dominant role in EB formation.
In the contrast to the results for AREG, no treatments,
including a single P injection, increased RANKL expres-
sion in the prepubertal 3-week-old BALB/c mammary
gland (Additional File 1, Figure S4).
Discussion
The present results demonstrate a novel progesterone
(P)-specific effect to cause end bud (EB) formation and
proliferation in the developing mammary gland both
before and during puberty. This effect was primarily
mediated through P-induced amphiregulin (AREG) via a
progesterone receptor (PR)-mediated mechanism, and
AREG expression was increased by P in both ducts and
EBs. Blocking AREG action by treatment with an epider-
mal growth factor receptor (EGFR) inhibitor completely
abrogated the effects of P on EB formation and prolifera-
tion, and significantly reduced proliferation within ducts.
Thus, AREG is an essential mediator of P-induced EB
formation and proliferation. To our knowledge, this is
the first report to demonstrate the sensitivity of the pre-
pubertal mammary gland to P.
Four EGF-family receptors are expressed in the mam-
mary gland at puberty: ErbB1 (EGF receptor/HERl),
ErbB2 (c-neu/HER2), ErbB3 (HER3), and ErbB4 (HER4)
[30]. Members of the EGF receptor family can homo-
and heterodimerize [31], with the possibility that ligands
for any of these receptors may be involved in pubertal
mammary gland development. In addition, there are cur-
rently 13 recognized ligands of the EGFR family: EGF,
heparin-binding (HB) EGF, transforming growth factor
(TGF) a, AREG, epiregulin (EREG), epigen (EPG), beta-
cellulin (BTC), and neuregulins (NRG) 1 to 6 [32]. Of the
EGFR ligands, at least seven of these ligands (EGF, HB-
EGF, TGF-a, AREG, EREG, EPG, BTC, NRG-1) have
been detected in the virgin mouse mammary gland [30].
Although some EGFR ligands, such as TGF-a and HB-
EGF, have been detected in pubertal EBs, AREG is the
most highly expressed EGFR ligand in ducts and EBs
during puberty, and AREG is required for normal ductal
morphogenesis [26]. AREG expression increases early in
puberty, starting around 18 days old, and is strongly
upregulated by estrogen (E) acting through ERa [19]. E
induces EB formation and proliferation in the pubertal
mammary gland through epithelial estrogen receptor a
(ERa)-induced AREG via a paracrine mechanism [19,33].
Our current studies extend the importance of AREG
in pubertal mammary gland development to also include
P-induced AREG as a mediator of EB formation and
proliferation. The ability of P acting through PR to
upregulate AREG expression is consistent with previous
studies in the adult mouse mammary gland [27] and
mouse uterus [28]. ERa and PR generally colocalize to
the same epithelial cells in the pubertal mammary gland
[14], and thus AREG is produced within the same lumi-
nal epithelial cell population, whether stimulated by P
or 17-b-estradiol (E2). AREG induced by either P or E2
binds to the EGFR, and EGFR inhibition abrogated the
effect of AREG on EB formation and proliferation.
Although the possible involvement of other EGFR
ligands should be noted, it is most likely that E and P
act together during normal development to produce
rapid ductal development, primarily through AREG. The
action of both hormones in ductal development may
allow more consistent stimulation throughout the estrus
cycle than would be afforded by either hormone alone.
These results demonstrate that pubertal mammary EB
development can be stimulated by E2 or P, and chal-
lenge the predominant understanding that all pubertal
mammary development is stimulated only by E. Thus, it
is important to consider that other factors/mechanisms
that increase expression of AREG may stimulate EB
development before and/or during puberty.
Proliferation of the epithelium in response to AREG
may be through direct stimulation by AREG or through
growth factors produced in the stroma [34]. P exerts its
effects in the mammary gland through acting on the
luminal epithelium, where PR is expressed [18,21]. How-
ever, stromal EGFR has been shown to be essential for
ductal development [35], and thus epithelium-derived
AREG is thought to bind to stromal EGFR to produce
normal ductal development and proliferation of epithe-
lial cells through an indirect mechanism [34]. We found
that all EB proliferation and most ductal proliferation in
the pubertal mammary gland was induced through
AREG, and that P induced proliferation of a large popu-
lation of PR+ cells in EBs in the pubertal mammary
gland after 5 days of treatment. A similar pattern of pro-
liferation of PR+ cells was also detected after E2 treat-
ment. A subset of luminal epithelial cells is hormone
receptor positive, expressing both ERa and PR [14].
These results suggest that either P or E-induced AREG
is capable of stimulating proliferation of both hormone-
receptor positive and negative cells within the mammary
epithelium. The sustained proliferation of hormone
receptor-positive cells during puberty contrasts with
results in the adult mammary gland [36]. AREG has
been shown to regulate the expansion of mouse mam-
mary epithelial progenitor cells [37], and a subset of the
hormone receptor-positive population may be an early
stem/progenitor population [38]. It is conceivable that
proliferation of the hormone receptor-positive putative
stem/progenitor cells may provide a critical target for
carcinogenesis and that AREG regulation of this prolif-
eration could contribute to breast cancer risk associated
with the pubertal window of susceptibility.
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Puberty, with increased hormone production leading to
EB stimulation and ductal development, has been shown
to be a critical period for mammary cancer susceptibility
[6-8]. E is considered to be the primary ovarian hormone
involved in EB stimulation and ductal elongation during
puberty, with E action mediated primarily through AREG
[9]; ductal growth is delayed in PR-knockout and RU486-
treated mice, showing that P is also capable of stimulating
ductal growth through PR [11]. However, no mechanism
for P stimulation of the pubertal mammary gland has been
described. Our results have now shown that P-induced
AREG causes EB stimulation in both the pubertal and the
prepubertal mammary glands. Many studies have focused
on the potential impact of environmental estrogens on
mammary gland development and cancer progression
(reviewed in [39]). Collectively, our current results and the
prior literature suggest that environmental factors that
influence P levels, P action, mimic P, or induce AREG can
also exert significant effects on the prepubertal and puber-
tal mammary gland. Consistent with this, the environmen-
tal pollutant perfluorooctanoic acid (PFOA) has been
shown to stimulate mammary gland development in mice
through increasing serum P levels, which led to an
increase in growth factors, including AREG, in the mam-
mary gland [40]. Thus, it is important to examine factors
that influence both E and P action in the pubertal mam-
mary gland, as they may affect breast cancer risk.
Further supporting the importance of AREG in the
mammary gland, we found similar proliferation and
AREG expression in both pubertal BALB/c and C57BL/
6 mice. Mice of these two different genetic backgrounds
respond differently to P in the adult mammary gland
[24], yet respond similarly to P during puberty by
increasing AREG expression leading to EB formation
and proliferation. In the normal rat mammary gland and
in hormone-dependent rat mammary cancers, AREG
has also been shown to mediate E and P signaling
through EGFR [41]. In the human breast, AREG is over-
expressed in most ERa-positive tumors, and expression
of EGFR is associated with poor prognosis and resis-
tance to hormone therapy [42]. Whereas the role of E
acting through AREG in mammary gland development
and breast cancer has been emphasized [43], the current
studies implicate P as another potential mediator of
AREG action. The importance of AREG in two different
mouse genetic backgrounds, in both the mouse and rat,
and in the human breast suggests that the AREG path-
way is broadly involved in ductal development and
mammary proliferation, and also in mammary cancer
development.
Another downstream effector of P, receptor activator
of NF-B ligand (RANKL), was also increased by P
treatment in BALB/c mice, and RANKL expression was
detected primarily in ducts in the pubertal mammary
gland. Inhibition of RANKL in the BALB/c mammary
gland significantly reduced P-induced proliferation in
ducts and to a lesser extent in EBs, but did not cause
EB regression. Proliferation in the adult mammary gland
is mediated by P via two distinct mechanisms; an early,
direct mitogenic effect on PR+ cells that is dependent
on cyclin D1, followed by a more robust proliferation of
PR- cells through RANKL [36]. Consistent with these
findings for RANKL, most adult mammary gland studies
conclude that P acts through a paracrine mechanism to
increase proliferation of PR- cells within the epithelium
[24,44-46]. It is likely that RANKL is acting as paracrine
mediator of P-induced proliferation within pubertal
mammary ducts, similar to its action in the adult mam-
mary gland. In contrast to the findings for AREG, P had
no effect on RANKL expression in the C57BL/6 mam-
mary gland, where RANKL expression required both E2
and P. The lack of pubertal regulation of RANKL by P
in the C57BL/6 mammary pubertal gland was consistent
with our previously observed lack of P-induced RANKL
in the C57BL/6 adult gland [24]. Overall, these results
suggest that RANKL is involved in P-induced ductal
development during puberty, but unlike AREG, RANKL
is not essential for P effects on EB formation.
Conclusions
In conclusion, these studies demonstrate that the prepu-
bertal and pubertal glands are sensitive to P, and lend
further support for the ability of P to influence mam-
mary ductal development, even in the absence of E.
Given that puberty may be an important period of can-
cer susceptibility, an understanding and elucidation of
possible endocrine disruption by factors that influence P
responses and/or AREG regulation in the prepubertal
and pubertal mammary gland must be considered, in
addition to factors that influence E responses. We pro-
pose that factors that influence P responsiveness and
other pathways that influence AREG production, in
addition to E, warrant further investigation in the prepu-
bertal and pubertal mammary gland.
Additional material
Additional file 1: Hormone responses in the pubertal and prepubertal
C57BL/6 mammary gland. Figure S1. Both 17-b-estradiol and
progesterone induce morphologic responses in the pubertal C57BL/
6 mammary gland. Pubertal 4-week-old C57BL/6 mice were OVX,
allowed to recover for 3 weeks, and then treated for 5 days with vehicle
control (C), E2, P, or E2+P, as described in the Materials and Methods
section. (A) Morphologic response to 5-day C, E2, P, or E2+P. Scale bar, 1
mm. (B) Immunofluorescent detection of PR expression. The values
represent the mean ± SEM PR-positive luminal cells (n = 3 animals per
treatment). The percentage of PR-positive cells in 5-day P-treated BALB/c
mice was less than control (*P < 0.05). The percentage of PR-positive
cells in 5-day P-treated C57BL/6 mice was less than control (#P < 0.05).
Figure S2. Both 17-b-estradiol and progesterone induce similar
proliferative responses in the C57BL/6 pubertal mammary gland.
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Pubertal 4-week-old C57BL/6 mice were OVX, allowed to recover for 3
weeks, and then treated for 5 days with vehicle control (C), E2, P, or E2
+P, as described in the Materials and Methods section. Proliferation
analysis by dual immunofluorescence was detection of BrdU and PR.
Total percentage of BrdU-positive cells and percentage of BrdU-positive
cells co-expressing PR in ducts and end buds are presented. The
percentages of BrdU-positive luminal epithelial cells in ducts in response
to E2, P, or E2+P treatment are greater than control (*P < 0.05). Figure
S3. Both 17-b-estradiol and progesterone regulate amphiregulin,
but co-stimulation with both 17-b-estradiol and progesterone is
required to regulate RANKL in the C57BL/6 pubertal mammary
gland. Pubertal 4-week-old C57BL/6 mice were OVX, allowed to recover
for 3 weeks, and then treated for 5 days with vehicle control (C), E2, P, or
E2+P, as described in the Materials and Methods section. (A)
Immunofluorescent detection of AREG (green) after E2, P, and E2+P
treatment. (B) Immunofluorescent detection in the mammary gland with
antibody against RANKL (green) in E2+P-treated C57BL/6 mammary
glands. Nuclei (A, B) were counterstained with DAPI (blue). Scale bar, 25
μm. Figure S4. Progesterone fails to induce RANKL in the
prepubertal mammary gland. Prepubertal 3-week-old BALB/c mice
were OVX, allowed to recover for 2 weeks, and then treated once with P,
as described in the Materials and Methods section. No RANKL (green)
expression was detected by immunofluorescence. Nuclei were
counterstained with DAPI (blue). Scale bar, 25 μm.
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